ArticleTherapeutic advances in medical oncology2021

Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial.

Gunn Huh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.